These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 19208592)

  • 21. Bosentan therapy for pulmonary arterial hypertension.
    Rubin LJ; Badesch DB; Barst RJ; Galie N; Black CM; Keogh A; Pulido T; Frost A; Roux S; Leconte I; Landzberg M; Simonneau G
    N Engl J Med; 2002 Mar; 346(12):896-903. PubMed ID: 11907289
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changes in right ventricular structure and function assessed using cardiac magnetic resonance imaging in bosentan-treated patients with pulmonary arterial hypertension.
    Chin KM; Kingman M; de Lemos JA; Warner JJ; Reimold S; Peshock R; Torres F
    Am J Cardiol; 2008 Jun; 101(11):1669-72. PubMed ID: 18489949
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study.
    Wilkins MR; Paul GA; Strange JW; Tunariu N; Gin-Sing W; Banya WA; Westwood MA; Stefanidis A; Ng LL; Pennell DJ; Mohiaddin RH; Nihoyannopoulos P; Gibbs JS
    Am J Respir Crit Care Med; 2005 Jun; 171(11):1292-7. PubMed ID: 15750042
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term outcome and effects of oral bosentan therapy in Taiwanese patients with advanced idiopathic pulmonary arterial hypertension.
    Hsu HH; Chen JS; Chen RJ; Ko WJ; Kuo SW; Wu ET; Wu MH; Wang JK; Lee YC
    Respir Med; 2007 Jul; 101(7):1556-62. PubMed ID: 17223329
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vascular endothelial growth factor, lipoporotein-associated phospholipase A2, sP-selectin and antiphospholipid antibodies, biological markers with prognostic value in pulmonary hypertension associated with chronic obstructive pulmonary disease and systemic lupus erithematosus.
    Tanaseanu C; Tudor S; Tamsulea I; Marta D; Manea G; Moldoveanu E
    Eur J Med Res; 2007 Apr; 12(4):145-51. PubMed ID: 17509958
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Comparison of adenosine versus iloprost by acute vasodilator test in patients of pulmonary arterial hypertension complicated with connective tissue diseases].
    Tian Z; Chen TB; Fang Q; Zeng XF; Liu YT; Li MT; Jiang XC; Gao P; Cheng KA; Wang Q
    Zhonghua Yi Xue Za Zhi; 2009 Aug; 89(30):2099-102. PubMed ID: 20058611
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial.
    Jaïs X; D'Armini AM; Jansa P; Torbicki A; Delcroix M; Ghofrani HA; Hoeper MM; Lang IM; Mayer E; Pepke-Zaba J; Perchenet L; Morganti A; Simonneau G; Rubin LJ;
    J Am Coll Cardiol; 2008 Dec; 52(25):2127-34. PubMed ID: 19095129
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension.
    McLaughlin VV; Oudiz RJ; Frost A; Tapson VF; Murali S; Channick RN; Badesch DB; Barst RJ; Hsu HH; Rubin LJ
    Am J Respir Crit Care Med; 2006 Dec; 174(11):1257-63. PubMed ID: 16946127
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bosentan therapy in patients with pulmonary arterial hypertension: the relationship between improvements in 6 minute walk distance and quality of life.
    Strange G; Keogh AM; Williams TJ; Wlodarczyk J; McNeil KD; Gabbay E
    Respirology; 2008 Sep; 13(5):674-82. PubMed ID: 18713089
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quality of life in pulmonary arterial hypertension: improvement and maintenance with bosentan.
    Keogh AM; McNeil KD; Wlodarczyk J; Gabbay E; Williams TJ
    J Heart Lung Transplant; 2007 Feb; 26(2):181-7. PubMed ID: 17258153
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcome of pulmonary hypertension subjects transitioned from intravenous prostacyclin to oral bosentan.
    Safdar Z
    Respir Med; 2009 Nov; 103(11):1688-92. PubMed ID: 19539456
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.
    Mathai SC; Girgis RE; Fisher MR; Champion HC; Housten-Harris T; Zaiman A; Hassoun PM
    Eur Respir J; 2007 Mar; 29(3):469-75. PubMed ID: 17079256
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of bosentan for pulmonary arterial hypertension in adults with congenital heart disease.
    Monfredi O; Griffiths L; Clarke B; Mahadevan VS
    Am J Cardiol; 2011 Nov; 108(10):1483-8. PubMed ID: 21943933
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.
    Johnson RF; Loyd JE; Mullican AL; Fink CA; Robbins IM
    J Heart Lung Transplant; 2007 Apr; 26(4):363-9. PubMed ID: 17403478
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease.
    Diller GP; Dimopoulos K; Kaya MG; Harries C; Uebing A; Li W; Koltsida E; Gibbs JS; Gatzoulis MA
    Heart; 2007 Aug; 93(8):974-6. PubMed ID: 17639112
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Eisenmenger syndrome in the adult--experience with new drugs for the treatment of pulmonary hypertension.
    Agapito AF; Sousa L; Oliveira JA; Feliciano J; Cacela D; Quininha J
    Rev Port Cardiol; 2005 Mar; 24(3):421-31. PubMed ID: 15929625
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bosentan for severe pulmonary arterial hypertension related to systemic sclerosis with interstitial lung disease.
    Ahmadi-Simab K; Hellmich B; Gross WL
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():44-8. PubMed ID: 16919010
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of bosentan on exercise capacity and quality of life in adults with pulmonary arterial hypertension associated with congenital heart disease with and without Down's syndrome.
    Duffels MG; Vis JC; van Loon RL; Nieuwkerk PT; van Dijk AP; Hoendermis ES; de Bruin-Bon RH; Bouma BJ; Bresser P; Berger RM; Mulder BJ
    Am J Cardiol; 2009 May; 103(9):1309-15. PubMed ID: 19406277
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Two years of multidisciplinary diagnostic and therapeutic experience in patients with pulmonary arterial hypertension].
    Tokgözoğlu L; Akdoğan A; Okutucu S; Kaya EB; Aytemir K; Ozkutlu H
    Turk Kardiyol Dern Ars; 2009 Sep; 37(6):378-83. PubMed ID: 20019450
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term effects of intermittent Iloprost infusion on pulmonary arterial pressure in connective tissue disease.
    Caravita S; Wu SC; Secchi MB; Dadone V; Bencini C; Pierini S
    Eur J Intern Med; 2011 Oct; 22(5):518-21. PubMed ID: 21925064
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.